Glycogen synthase kinase-3β (GSK-3β) inhibitors AR-A014418 and B6B3O prevent human immunodeficiency virus–mediated neurotoxicity in primary human neurons

References

• Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM (2000). Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain Res 879: 42–49.
   Google Scholar
• Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, Radesater AC, Jerning E, Markgren PO, Borgegard T, Nylof M, Gimenez-Cassina A, Hernandez F, Lucas JJ, Diaz-Nido J, Avila J (2003). Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 278: 45937–45945.
   PubMed Web of Science ®Google Scholar
• Budka H, Wiley CA, Kleihues P, Artigas J, Asbury AK, Cho ES, Cornblath DR, Dal Canto MC, DeGirolami U, Dickson D (1991). HIV-associated disease of the nervous system: review of nomenclature and proposal for neuropathology-based terminology. Brain Pathol 1: 143–152.
   PubMed Web of Science ®Google Scholar
• Cherner M, Masliah E, Ellis RJ, Marcotte TD, Moore DJ, Grant I, Heaton RK (2002). Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 59: 1563–1567.
   PubMed Web of Science ®Google Scholar
• Clifford DB (2008). HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 16: 94–98.
   PubMedGoogle Scholar
• Cohen P, Goedert M (2004). GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3: 479–487.
   PubMed Web of Science ®Google Scholar
• Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA (2007). Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol 2: 93–96.
   PubMedGoogle Scholar
• Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE (2003). Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 23: 9162–9170.
   PubMed Web of Science ®Google Scholar
• Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE (2005). Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25: 8375–8385.
   PubMed Web of Science ®Google Scholar
• Everall IP, Bell C, Mallory M, Langford D, Adame A, Rockestein E, Masliah E (2002). Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 21: 3: 493–501.
   PubMed Web of Science ®Google Scholar
• Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999). Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9: 209–217.
   PubMed Web of Science ®Google Scholar
• Everall IP, Luthert PJ, Lantos PL (1991). Neuronal loss in the frontal cortex in HIV infection. Lancet 337: 1119–1121.
   PubMed Web of Science ®Google Scholar
• Everall IP, Luthert PJ, Lantos PL (1993). Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatry 56: 481–486.
   PubMedGoogle Scholar
• Everall IP, Trillo-Pazos G, Bell C, Mallory M, Sanders V, Masliah E (2001). Amelioration of neurotoxic effects of HIV envelope protein gp120 by fibroblast growth factor: a strategy for neuroprotection. J Neuropathol Exp Neurol 60: 293–301.
   PubMed Web of Science ®Google Scholar
• Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, Chen Y, Hauser KF (2001). Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 102: 3: 555–563.
   PubMed Web of Science ®Google Scholar
• Garden G, Budd S, Tsai E, Hanson L, Kaul M, Emilia D, Friedlander R, Yuan J, Masliah E, Lipton S (2002). Caspase cascades in human immunodeficiency virus-associated neurodegeneration. J Neurosci 22: 4015–4024.
   PubMedGoogle Scholar
• Hashimoto M, Sagara Y, Langford D, Everall IP, Mallory M, Everson A, Digicaylioglu M, Masliah E (2001). Fibroblast growth factor 1 regulates signaling via the glycogen synthase kinase-3beta pathway. Implications for neuroprotection. J Biol Chem 277: 36: 32985–32991.
   Google Scholar
• Kaul M, Garden G, Lipson SA (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988–994.
   PubMed Web of Science ®Google Scholar
• Klein PS, Melton DA (1996). A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93: 8455–8459.
   PubMed Web of Science ®Google Scholar
• Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008). Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28: 2576–2588.
   PubMed Web of Science ®Google Scholar
• Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, Durelle J, Grant I, Everall I (2006). Lithium improves HIV-associated neurocognitive impairment. AIDS 20: 1885–1888.
   PubMed Web of Science ®Google Scholar
• Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S (1999). HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 73: 578–586.
   PubMed Web of Science ®Google Scholar
• Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997). Dendritic injury is a pathological substrate for Human Immunodeficiency Virus-related cognitive disorders. Ann Neurol 42: 963–972.
   PubMed Web of Science ®Google Scholar
• Mattson MP, Wang H, Michaelis EK (1991). Developmental expression, compartmentalization, and possible role in excitotoxicity of a putative NMDA receptor protein in cultured hippocampal neurons. Brain Res 565: 94–108.
   Web of Science ®Google Scholar
• Meijer L, Flajolet M, Greengard P (2004). Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25: 471–480.
   PubMed Web of Science ®Google Scholar
• Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008). Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 20: 25–31.
   PubMed Web of Science ®Google Scholar
• Packard M, Mathew D, Budnik V (2003). Wnts and TGF beta in synaptogenesis: old friends signalling at new places. Nat Rev Neurosci 4: 113–120.
   Google Scholar
• Rowe MK, Wiest C, Chuang DM (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 31: 920–931.
   PubMed Web of Science ®Google Scholar
• Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H (2006). Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 66: 919–921.
   PubMed Web of Science ®Google Scholar
• Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, Gelbard HA (2001). Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 13: 1913–1922.
   PubMedGoogle Scholar
• Trillo-Pazos G, Kandanearatchi A, Eyeson J, King D, Vyakarnam A, Everall I (2004). Infection of stationary human brain aggregates with HIV-1 sf162 and IIIB results in transient neuronal damage and neurotoxicity. Neuropathol Appl Neurobiol 30: 136–147.
   Web of Science ®Google Scholar
• Trillo-Pazos G, McFarlane-Abdulla E, Campbell IC, Pilkington GJ, Everall IP (2000). Recombinant nef HIV-IIIB protein is toxic to human neurons in culture. Brain Res 864: 315–326.
   PubMedGoogle Scholar
• Zhang Y, Goodyer C, LeBlanc A (2000). Selective and protracted apoptosis in human primary neurons microinjected with active caspase −3, −6, −7, and −8. J Neurosci 20: 185–200.
   Google Scholar